BARRIER THERAPEUTICS INC 4
4 · BARRIER THERAPEUTICS INC · Filed Apr 30, 2004
Insider Transaction Report
Form 4
Transactions
- Conversion
Series B Convertible Preferred Stock
2004-04-28−4,666,667→ 0 total→ Common Stock (2,333,333 underlying) - Conversion
Series C Convertible Preferred Stock
2004-04-28−842,810→ 0 total→ Common Stock (421,405 underlying) - Conversion
Common Stock, $.0001 par value
2004-04-28+2,754,738→ 2,754,738 total
Footnotes (3)
- [F1]On April 28, 2004, each share of the Issuer's Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into 0.5 shares of Common Stock. This gives effect to the 1-for-2 reverse stock split that occurred on April 28, 2004.
- [F2]All of the securities reported herein are held for the account of Perseus-Soros BioPharmaceutical Fund, L.P. ("Perseus-Soros"). Perseus-Soros Partners, LLC, a Delaware limited liability company ("Perseus-Soros Partners"), is the general partner of Perseus-Soros. Perseus BioTech Fund Partners, LLC, a Delaware limited liability company ("Perseus Partners"), and SFM Participation, L.P., a Delaware limited partnership ("SFM Participation"), are the managing members of Perseus-Soros Partners. Perseus EC, L.L.C., a Delaware limited liability company ("Perseus EC"), is the managing member of Perseus Partners. Perseuspur, LLC, a Delaware limited liability company ("Perseuspur"), is a member of Perseus EC. Mr. Frank H. Pearl ("Mr. Pearl") is the sole member of Perseuspur.
- [F3]SFM AH LLC, a Delaware limited liability company ("SFM AH"), is the general partner of SFM Participation. The sole managing member of SFM AH is Soros Fund Management LLC, a Delaware limited liability company ("SFM LLC"). Mr. George Soros serves as Chairman of SFM LLC.